ArticleFrontiers in public health2026
Cost-effectiveness analysis of neoadjuvant docetaxel plus androgen deprivation therapy before radical prostatectomy in high-risk localized prostate cancer.
Qi Liu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.